Comparable antigenicity and immunogenicity of oligomeric forms of a novel, acute HIV-1 subtype C gp145 envelope for use in preclinical and clinical vaccine research

Lindsay Wieczorek, Shelly J. Krebs, Vaniambadi Kalyanaraman, Stephen Whitney, Sodsai Tovanabutra, Carlos G. Moscoso, Eric Sanders-Buell, Constance Williams, Bonnie Slike, Sebastian Molnar, Vincent Dussupt, S. Munir Alam, Agnes Laurence Chenine, Tina Tong, Edgar L. Hill, Hua Xin Liao, Michael Hoelscher, Leonard Maboko, Susan Zolla-Pazner, Barton F. HaynesMichael Pensiero, Francine McCutchan, Shawyon Malek-Salehi, R. Holland Cheng, Merlin L. Robb, Thomas VanCott, Nelson L. Michael, Mary A. Marovich, Carl R. Alving, Gary R. Matyas, Mangala Rao, Victoria R. Polonis

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Eliciting broadly reactive functional antibodies remains a challenge in human immunodeficiency virus type 1 (HIV-1) vaccine development that is complicated by variations in envelope (Env) subtype and structure. The majority of new global HIV-1 infections are subtype C, and novel antigenic properties have been described for subtype C Env proteins. Thus, an HIV-1 subtype C Env protein (CO6980v0c22) from an infected person in the acute phase (Fiebig stage I/II) was developed as a research reagent and candidate immunogen. The gp145 envelope is a novel immunogen with a fully intact membrane-proximal external region (MPER), extended by a polylysine tail. Soluble gp145 was enriched for trimers that yielded the expected "fan blade" motifs when visualized by cryoelectron microscopy. CO6980v0c22 gp145 reacts with the 4E10, PG9, PG16, and VRC01 HIV-1 neutralizing monoclonal antibodies (MAbs), as well as the V1/V2-specific PGT121, 697, 2158, and 2297 MAbs. Different gp145 oligomers were tested for immunogenicity in rabbits, and purified dimers, trimers, and larger multimers elicited similar levels of crosssubtype binding and neutralizing antibodies to tier 1 and some tier 2 viruses. Immunized rabbit sera did not neutralize the highly resistant CO6980v0c22 pseudovirus but did inhibit the homologous infectious molecular clone in a peripheral blood mononuclear cell (PBMC) assay. This Env is currently in good manufacturing practice (GMP) production to be made available for use as a clinical research tool and further evaluation as a candidate vaccine.

Original languageEnglish (US)
Pages (from-to)7478-7493
Number of pages16
JournalJournal of Virology
Volume89
Issue number15
DOIs
StatePublished - 2015

Fingerprint

Human immunodeficiency virus 1
HIV-1
Vaccines
immune response
vaccines
Protein C
Neutralizing Antibodies
neutralizing antibodies
Research
monoclonal antibodies
Pseudovirus
rabbits
Monoclonal Antibodies
Rabbits
antigens
Cryoelectron Microscopy
good manufacturing practices
Polylysine
vaccine development
Virus Diseases

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Comparable antigenicity and immunogenicity of oligomeric forms of a novel, acute HIV-1 subtype C gp145 envelope for use in preclinical and clinical vaccine research. / Wieczorek, Lindsay; Krebs, Shelly J.; Kalyanaraman, Vaniambadi; Whitney, Stephen; Tovanabutra, Sodsai; Moscoso, Carlos G.; Sanders-Buell, Eric; Williams, Constance; Slike, Bonnie; Molnar, Sebastian; Dussupt, Vincent; Munir Alam, S.; Chenine, Agnes Laurence; Tong, Tina; Hill, Edgar L.; Liao, Hua Xin; Hoelscher, Michael; Maboko, Leonard; Zolla-Pazner, Susan; Haynes, Barton F.; Pensiero, Michael; McCutchan, Francine; Malek-Salehi, Shawyon; Holland Cheng, R.; Robb, Merlin L.; VanCott, Thomas; Michael, Nelson L.; Marovich, Mary A.; Alving, Carl R.; Matyas, Gary R.; Rao, Mangala; Polonis, Victoria R.

In: Journal of Virology, Vol. 89, No. 15, 2015, p. 7478-7493.

Research output: Contribution to journalArticle

Wieczorek, L, Krebs, SJ, Kalyanaraman, V, Whitney, S, Tovanabutra, S, Moscoso, CG, Sanders-Buell, E, Williams, C, Slike, B, Molnar, S, Dussupt, V, Munir Alam, S, Chenine, AL, Tong, T, Hill, EL, Liao, HX, Hoelscher, M, Maboko, L, Zolla-Pazner, S, Haynes, BF, Pensiero, M, McCutchan, F, Malek-Salehi, S, Holland Cheng, R, Robb, ML, VanCott, T, Michael, NL, Marovich, MA, Alving, CR, Matyas, GR, Rao, M & Polonis, VR 2015, 'Comparable antigenicity and immunogenicity of oligomeric forms of a novel, acute HIV-1 subtype C gp145 envelope for use in preclinical and clinical vaccine research', Journal of Virology, vol. 89, no. 15, pp. 7478-7493. https://doi.org/10.1128/JVI.00412-15
Wieczorek, Lindsay ; Krebs, Shelly J. ; Kalyanaraman, Vaniambadi ; Whitney, Stephen ; Tovanabutra, Sodsai ; Moscoso, Carlos G. ; Sanders-Buell, Eric ; Williams, Constance ; Slike, Bonnie ; Molnar, Sebastian ; Dussupt, Vincent ; Munir Alam, S. ; Chenine, Agnes Laurence ; Tong, Tina ; Hill, Edgar L. ; Liao, Hua Xin ; Hoelscher, Michael ; Maboko, Leonard ; Zolla-Pazner, Susan ; Haynes, Barton F. ; Pensiero, Michael ; McCutchan, Francine ; Malek-Salehi, Shawyon ; Holland Cheng, R. ; Robb, Merlin L. ; VanCott, Thomas ; Michael, Nelson L. ; Marovich, Mary A. ; Alving, Carl R. ; Matyas, Gary R. ; Rao, Mangala ; Polonis, Victoria R. / Comparable antigenicity and immunogenicity of oligomeric forms of a novel, acute HIV-1 subtype C gp145 envelope for use in preclinical and clinical vaccine research. In: Journal of Virology. 2015 ; Vol. 89, No. 15. pp. 7478-7493.
@article{9345d0f66d264ace90adfc706c99f478,
title = "Comparable antigenicity and immunogenicity of oligomeric forms of a novel, acute HIV-1 subtype C gp145 envelope for use in preclinical and clinical vaccine research",
abstract = "Eliciting broadly reactive functional antibodies remains a challenge in human immunodeficiency virus type 1 (HIV-1) vaccine development that is complicated by variations in envelope (Env) subtype and structure. The majority of new global HIV-1 infections are subtype C, and novel antigenic properties have been described for subtype C Env proteins. Thus, an HIV-1 subtype C Env protein (CO6980v0c22) from an infected person in the acute phase (Fiebig stage I/II) was developed as a research reagent and candidate immunogen. The gp145 envelope is a novel immunogen with a fully intact membrane-proximal external region (MPER), extended by a polylysine tail. Soluble gp145 was enriched for trimers that yielded the expected {"}fan blade{"} motifs when visualized by cryoelectron microscopy. CO6980v0c22 gp145 reacts with the 4E10, PG9, PG16, and VRC01 HIV-1 neutralizing monoclonal antibodies (MAbs), as well as the V1/V2-specific PGT121, 697, 2158, and 2297 MAbs. Different gp145 oligomers were tested for immunogenicity in rabbits, and purified dimers, trimers, and larger multimers elicited similar levels of crosssubtype binding and neutralizing antibodies to tier 1 and some tier 2 viruses. Immunized rabbit sera did not neutralize the highly resistant CO6980v0c22 pseudovirus but did inhibit the homologous infectious molecular clone in a peripheral blood mononuclear cell (PBMC) assay. This Env is currently in good manufacturing practice (GMP) production to be made available for use as a clinical research tool and further evaluation as a candidate vaccine.",
author = "Lindsay Wieczorek and Krebs, {Shelly J.} and Vaniambadi Kalyanaraman and Stephen Whitney and Sodsai Tovanabutra and Moscoso, {Carlos G.} and Eric Sanders-Buell and Constance Williams and Bonnie Slike and Sebastian Molnar and Vincent Dussupt and {Munir Alam}, S. and Chenine, {Agnes Laurence} and Tina Tong and Hill, {Edgar L.} and Liao, {Hua Xin} and Michael Hoelscher and Leonard Maboko and Susan Zolla-Pazner and Haynes, {Barton F.} and Michael Pensiero and Francine McCutchan and Shawyon Malek-Salehi and {Holland Cheng}, R. and Robb, {Merlin L.} and Thomas VanCott and Michael, {Nelson L.} and Marovich, {Mary A.} and Alving, {Carl R.} and Matyas, {Gary R.} and Mangala Rao and Polonis, {Victoria R.}",
year = "2015",
doi = "10.1128/JVI.00412-15",
language = "English (US)",
volume = "89",
pages = "7478--7493",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "15",

}

TY - JOUR

T1 - Comparable antigenicity and immunogenicity of oligomeric forms of a novel, acute HIV-1 subtype C gp145 envelope for use in preclinical and clinical vaccine research

AU - Wieczorek, Lindsay

AU - Krebs, Shelly J.

AU - Kalyanaraman, Vaniambadi

AU - Whitney, Stephen

AU - Tovanabutra, Sodsai

AU - Moscoso, Carlos G.

AU - Sanders-Buell, Eric

AU - Williams, Constance

AU - Slike, Bonnie

AU - Molnar, Sebastian

AU - Dussupt, Vincent

AU - Munir Alam, S.

AU - Chenine, Agnes Laurence

AU - Tong, Tina

AU - Hill, Edgar L.

AU - Liao, Hua Xin

AU - Hoelscher, Michael

AU - Maboko, Leonard

AU - Zolla-Pazner, Susan

AU - Haynes, Barton F.

AU - Pensiero, Michael

AU - McCutchan, Francine

AU - Malek-Salehi, Shawyon

AU - Holland Cheng, R.

AU - Robb, Merlin L.

AU - VanCott, Thomas

AU - Michael, Nelson L.

AU - Marovich, Mary A.

AU - Alving, Carl R.

AU - Matyas, Gary R.

AU - Rao, Mangala

AU - Polonis, Victoria R.

PY - 2015

Y1 - 2015

N2 - Eliciting broadly reactive functional antibodies remains a challenge in human immunodeficiency virus type 1 (HIV-1) vaccine development that is complicated by variations in envelope (Env) subtype and structure. The majority of new global HIV-1 infections are subtype C, and novel antigenic properties have been described for subtype C Env proteins. Thus, an HIV-1 subtype C Env protein (CO6980v0c22) from an infected person in the acute phase (Fiebig stage I/II) was developed as a research reagent and candidate immunogen. The gp145 envelope is a novel immunogen with a fully intact membrane-proximal external region (MPER), extended by a polylysine tail. Soluble gp145 was enriched for trimers that yielded the expected "fan blade" motifs when visualized by cryoelectron microscopy. CO6980v0c22 gp145 reacts with the 4E10, PG9, PG16, and VRC01 HIV-1 neutralizing monoclonal antibodies (MAbs), as well as the V1/V2-specific PGT121, 697, 2158, and 2297 MAbs. Different gp145 oligomers were tested for immunogenicity in rabbits, and purified dimers, trimers, and larger multimers elicited similar levels of crosssubtype binding and neutralizing antibodies to tier 1 and some tier 2 viruses. Immunized rabbit sera did not neutralize the highly resistant CO6980v0c22 pseudovirus but did inhibit the homologous infectious molecular clone in a peripheral blood mononuclear cell (PBMC) assay. This Env is currently in good manufacturing practice (GMP) production to be made available for use as a clinical research tool and further evaluation as a candidate vaccine.

AB - Eliciting broadly reactive functional antibodies remains a challenge in human immunodeficiency virus type 1 (HIV-1) vaccine development that is complicated by variations in envelope (Env) subtype and structure. The majority of new global HIV-1 infections are subtype C, and novel antigenic properties have been described for subtype C Env proteins. Thus, an HIV-1 subtype C Env protein (CO6980v0c22) from an infected person in the acute phase (Fiebig stage I/II) was developed as a research reagent and candidate immunogen. The gp145 envelope is a novel immunogen with a fully intact membrane-proximal external region (MPER), extended by a polylysine tail. Soluble gp145 was enriched for trimers that yielded the expected "fan blade" motifs when visualized by cryoelectron microscopy. CO6980v0c22 gp145 reacts with the 4E10, PG9, PG16, and VRC01 HIV-1 neutralizing monoclonal antibodies (MAbs), as well as the V1/V2-specific PGT121, 697, 2158, and 2297 MAbs. Different gp145 oligomers were tested for immunogenicity in rabbits, and purified dimers, trimers, and larger multimers elicited similar levels of crosssubtype binding and neutralizing antibodies to tier 1 and some tier 2 viruses. Immunized rabbit sera did not neutralize the highly resistant CO6980v0c22 pseudovirus but did inhibit the homologous infectious molecular clone in a peripheral blood mononuclear cell (PBMC) assay. This Env is currently in good manufacturing practice (GMP) production to be made available for use as a clinical research tool and further evaluation as a candidate vaccine.

UR - http://www.scopus.com/inward/record.url?scp=84937689183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937689183&partnerID=8YFLogxK

U2 - 10.1128/JVI.00412-15

DO - 10.1128/JVI.00412-15

M3 - Article

C2 - 25972551

AN - SCOPUS:84937689183

VL - 89

SP - 7478

EP - 7493

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 15

ER -